FDA approves talquetamab, a first-in-class bispecific antibody, for heavily pretreated multiple myeloma

Later-Stage HumanFDA-approved for the exact stated cancer/useNot addressed

The FDA granted accelerated approval to talquetamab-tgvs (Talvey), the first bispecific antibody directed at GPRC5D (a protein overexpressed on myeloma cells but with limited expression on normal blood cells), for adult patients with relapsed or refractory multiple myeloma who have already received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The approval was supported by the single-arm, open-label, phase 1/2 MonumenTAL-1 trial (ClinicalTrials.gov NCT04634552; primary publication in the New England Journal of Medicine, DOI 10.1056/NEJMoa2204591), which enrolled heavily pretreated patients across multiple dosing cohorts. Talquetamab works by simultaneously binding GPRC5D on myeloma cells and CD3 on the patient’s own T-cells, redirecting those T-cells to attack the cancer.

What This Means

In the single-arm, open-label, phase 1/2 MonumenTAL-1 trial, talquetamab produced meaningful, durable responses in patients with heavily pretreated, relapsed or refractory multiple myeloma who had already exhausted the major available drug classes. This supported FDA accelerated approval, a pathway used when a drug shows a meaningful response rate in an area of unmet medical need, ahead of confirmatory data on longer-term outcomes like survival.

What This Doesn't Mean

This is a single-arm trial (no randomized comparison group), the basis for an ACCELERATED approval, not a full/traditional approval — continued approval may depend on results from a confirmatory trial verifying clinical benefit. This record makes no claim about talquetamab's effect on overall survival, which was not this trial's design.

Why It Matters

A first-in-class bispecific antibody targeting a novel protein (GPRC5D) gives patients who have already failed every major existing multiple myeloma drug class a genuinely new mechanism of action to try — a real, meaningful option in a population with historically very limited choices left.

Promise & Proof

Proof — strength of the evidence 5 / 5

Base score from evidence stage: Later-Stage Human.
FDA-approved for the exact stated cancer/use.

Promise — potential significance if later evidence holds up 3 / 5

Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
The record includes substantive editorial reasoning about why this discovery matters.
A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with relapsed or refractory multiple myeloma who had already received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, enrolled in the single-arm, open-label MonumenTAL-1 trial. (Adults)

Restricted to patients meeting the specific prior-treatment criteria (at least 4 prior lines including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody) — not a first-line or early-line therapy. This is a T-cell-engaging bispecific antibody, a drug class with known risks including cytokine release syndrome and neurotoxicity that require specialized monitoring; this record does not itself detail the full safety profile and that should be added before publication.

Full evidence details

Study design: Non-randomized trial
Sample size: 187

Funding & Conflicts

Sponsor/developer: Janssen Biotech, Inc. (Johnson & Johnson) — not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

United States (FDA)

Status: FDA-approved for the exact stated cancer/use
Indication: Adults with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Biomarker requirement: GPRC5D-expressing multiple myeloma (target of the bispecific antibody; not a patient-selection biomarker test)
Decision date: 2023-08-09
Source: Regulator record (opens in a new tab)

Guideline positions

Guideline

Position: Not addressed
Last verified: 2026-08-13

Primary evidence supporting this story

MonumenTAL-1 trial primary results: talquetamab in relapsed/refractory multiple myeloma (NEJM) (opens in a new tab) (Peer-reviewed paper) [Peer-reviewed] 10.1056/NEJMoa2204591 Load-bearing source DOI 10.1056/NEJMoa2204591, PMID 36507686
MonumenTAL-1 trial primary results: talquetamab in relapsed/refractory multiple myeloma (NEJM). DOI 10.1056/NEJMoa2204591, PMID 36507686.

Additional context

MonumenTAL-1 trial registry (opens in a new tab) (Clinical-trial registry) NCT04634552 NCT04634552
MonumenTAL-1 trial registry. NCT04634552.

Why Should I Trust This?

1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

2026-08-13 Status change — Status changed from "Legacy / Unverified" to "In editorial review".
2026-08-13 Status change — Status changed from "In editorial review" to "Verified".

Last reviewed 2026-08-13